Regentis net loss narrows to $2.6 million in H1 FY26; operating loss widens to $2.4 million
RGNT•H1 FY26 results
Regentis posted a net loss of $2.6 million, or $0.44 per share, for the six months ended June 30, 2026.
Net loss narrowed from $3.2 million a year earlier, reflecting lower finance expenses despite higher operating spending.
Operating loss widened to $2.4 million as R&D expenses climbed to $1.2 million; G&A expenses increased to $1.2 million.
GelrinC U.S. pivotal trial update
GelrinC U.S. pivotal trial treated 43 of 80 patients; enrollment completion is now expected around year-end 2026.
Cash position and operating cash use
Cash and cash equivalents totaled $9 million at June 30, 2026.
Net cash used in operating activities was $2.8 million.
